Teva Advances NYSE Listing With ADS Exchange Plan
I'm LongbridgeAI, I can summarize articles.Teva Pharmaceutical executed an amendment to its deposit agreement with Citibank, advancing its plan to list ordinary shares on the NYSE. A mandatory one-for-one exchange of American Depositary Shares (ADS) into ordinary shares will occur on September 14, 2026, terminating the ADS program. Analysts maintain a 'Buy' rating with a $40 price target, citing improving fundamentals and strong earnings guidance, despite concerns over elevated leverage and revenue headwinds.
An update from Teva Pharmaceutical ( (TEVA) ) is now available.
On August 31, 2026, Teva Pharmaceutical Industries Ltd. executed an amendment to its Second Amended and Restated Deposit Agreement with Citibank, N.A. and updated the form of American depositary receipt, as part of its previously disclosed plan to list its ordinary shares on the New York Stock Exchange. The amendment establishes a mechanism for the mandatory one-for-one exchange of American depositary shares into ordinary shares, with the ADS program slated to terminate at the open of business on September 14, 2026, at which point all outstanding ADSs will be canceled and replaced by an equal number of economically equivalent NYSE-listed ordinary shares, effectively transitioning investors from the ADS structure to direct ownership of listed equity.
The most recent analyst rating on (TEVA) stock is a Buy
with a $40.00 price target.
To see the full list of analyst forecasts on Teva Pharmaceutical stock,
see the TEVA Stock Forecast page.
Spark’s Take on TEVA Stock
According to Spark, TipRanks’ AI Analyst, TEVA is a Outperform.
The score is driven primarily by improving fundamentals and a strong, upbeat earnings call (guidance raises, innovative portfolio growth, margin expansion, and higher free cash flow). This is supported by constructive technical positioning above key moving averages. Offsetting factors are still-elevated leverage, recent top-line pressure (TTM revenue decline and generics headwinds), and a valuation that appears only moderate with no dividend yield support.
To see Spark’s full report on TEVA stock,
click here.
More about Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company whose ordinary shares are traded and can be represented by American depositary shares, with each ADS corresponding to one ordinary share with a par value of NIS 0.10. The company utilizes depositary arrangements via Citibank, N.A. to facilitate trading of its equity by holders and beneficial owners of ADSs in international capital markets.
Average Trading Volume: 5,542,147
Technical Sentiment Signal: Buy
Current Market Cap: $42.47B